Sino Biopharm, partenaire d'Iventiva, autorisé à développer le lanifibranor en Chine
Sino Biopharm, partenaire d'Iventiva, autorisé à développer le lanifibranor en Chine
25 mai (Reuters) - Inventiva SA:
* ANNONCE QUE SON PARTENAIRE SINO BIOPHARM A REÇU L'APPROBATION DE SA DEMANDE D'IND PAR LA NMPA POUR DÉMARRER LE DÉVELOPPEMENT CLINIQUE DE LANIFIBRANOR EN CHINE (Rédaction de Paris)
©2023 Thomson Reuters,
all rights reserved. Reuters content is the intellectual property of Thomson Reuters
or its third party content providers. Any copying, republication or redistribution
of Reuters content, including by framing or similar means, is expressly prohibited
without the prior written consent of Thomson Reuters. Thomson Reuters shall not
be liable for any errors or delays in content, or for any actions taken in reliance
thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its
affiliated companies.
